Samarium SM 153 Lexidronam Articles
Cytogen's 3rd-qtr loss improves 11% on sales
12 November 2007
Cytogen's 2nd-qtr net loss widens to $10.4M
20 August 2007
Cytogen's 4th-qtr 2006 losses up 85.4%
12 March 2007
Cytogen's 3rd-qtr 2006 net loss improves 24%
13 November 2006
Stock Commentary - New York week to May 8, 2006
15 May 2006
Cytogen: "less Quadramet toxicity via ILP"
17 April 2006
Stock Commentary - New York week to Dec 12
19 December 2005
Cytogen's 2nd qtr loss widens 75%
15 August 2005
Stock Commentary - New York
23 May 2005
Stock Commentary - New York
5 July 2004
Cytogen's 4th-qtr sales up 28% to $3.4 m
15 March 2004
Cytogen reacquires rights to pain product
23 June 2003
Cytogen's Quadramet efficacy in tumors
16 June 2003
Cytogen 1st qtr sales advance 25%
1 May 2001
Further radiopharma inroad for Schering AG
8 October 1999
Stock Commentary New York
5 November 1998
Cytogen Close To New Deal On Quadramet?
20 October 1998
Beaufour Ipsen Outlines Growth Strategy to 2000
7 October 1998
Stock Commentary New York
9 July 1998
DuPont Merck/Cytogen Keep Quadramet Deal
27 May 1998
EMEA CPMP Plenary Meeting In February
10 March 1998
Pramipexole Approved In The European Union
5 March 1998
More US Year-End 1997 Corporate Results
24 February 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
3rd Qtr Revenues Up For US Drug & Biotech Firms
6 November 1997
US Drug & Biotech Firms Post Quarterly Results
14 August 1997
US Quarterly Financial Results Round-Up
12 May 1997
NEW YORK STOCK COMMENT
7 April 1997
First Approval For Cytogen's Quadramet
7 April 1997
Cytogen Files NDS In Canada For Quardramet
17 March 1997
Investment Of $1.47 Million In Cytogen
16 September 1996
US Corporate Results Round-Up
27 May 1996
Cytogen's Quadramet
27 May 1996
Important Developments For US Biotechnology Cos
19 February 1996
Cytogen Submits NDA In USA For Quadramet
19 June 1995
Showing 1-38 of 38 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
